(UroToday.com) The 2025 AUA annual meeting featured an advanced prostate cancer session and a presentation by Dr. Neal Shore discussing health-related quality of life, pain and safety outcomes in the ...

PSMA-targeted radioligand therapy with 177Lu-PSMA-617 has been shown to improve survival outcomes in select pre-treated mCRPC patients; however, disease control is typically short-term. PSMA may be ...

After a median follow-up of 20.9 months, patients on 177Lu-PSMA-617 had radiographic progression-free survival (PFS) of 8.7 months, compared to 3.4 months in the control group, and overall ...

The deal sees Endocyte acquire an exclusive worldwide licence for ABX’s phase 3-ready prostate cancer candidate 177Lu-PSMA-617. This is a radioligand therapeutic (RLT) that targets the prostate ...

The 177Lu-PSMA-617 treatment allows for more patients to benefit from the treatment. It enables doctors to determine how well a treatment is actually working. Patients have superior disease ...

"In an earlier study, we found that patients whose kidney function worsened after lutetium-177 PSMA therapy showed changes in kidney structure ... Decline after 177Lu Prostate-specific Membrane ...

PSMA therapy uses two drugs joined together. One is a molecule called PSMA-617. It finds and attaches to PSMA on cancer cells. The other is a radioactive medicine named lutetium 177 (Lu 177).

Ianalumab Phase II data in immune thrombocytopenia and longer-term pelabresib Phase III data in myelofibrosis show breadth of pipeline in hematologic diseases Basel, May 15, 2025 - Novartis will ...